<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639857</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-17-13680</org_study_id>
    <nct_id>NCT03639857</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone</brief_title>
  <official_title>A Comparative Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Weinstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Central Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the efficacy of 532nm Potassium Titanyl Phosphate (KTP) laser and&#xD;
      1064 nm Neodymium-doped Yttrium Aluminum Garnet (Nd:YAG) laser as adjuncts to topical&#xD;
      corticosteroids in the treatment of cutaneous lupus erythematosus versus topical&#xD;
      corticosteroids alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Time and resource constraints&#xD;
  </why_stopped>
  <start_date type="Actual">August 17, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Limited CLASI</measure>
    <time_frame>2 Months</time_frame>
    <description>The investigators are using a limited Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scoring system to classify specific lesions the investigators are measuring. The total limited CLASI reflects the sum of both active and damage CLASI, resulting in a score ranging from 0 to 8. A higher score indicates more severe disease. Score is assessed by the investigators.&#xD;
The limited active CLASI for a lesion will include the following:&#xD;
Erythema (ranging from 0 = absent to 3 = dark red/purple)&#xD;
Scale/Hypertrophy (ranging from 0 = absent to 2 = verrucous/ hypertrophic)&#xD;
The addition of these scores result in a total limited active CLASI score of the studied lesion, ranging from 0 to 5.&#xD;
The limited damage CLASI for a lesion will include the following:&#xD;
Dyspigmentation (0 = absent or 1 = present)&#xD;
Scarring/Atrophy/Panniculitis (ranging from 0 = absent to 2 = severely atrophic scarring or panniculitis).&#xD;
The addition of these scores result in a</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS for Appearance</measure>
    <time_frame>2 Months</time_frame>
    <description>The investigators are using a VAS (visual analog scale) to measure patient assessment of the appearance of the lesion. The scale ranges from 0-10, with 10 being very satisfied and 0 being no satisfaction at all.&#xD;
A score of 0 will represent a cosmetically fully unsatisfactory result and 10 will represent cosmetically excellent result.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS for Pain</measure>
    <time_frame>1 Month</time_frame>
    <description>The investigators are using a VAS (visual analog scale) to assess pain of the laser treatment. The participant rates the pain of the laser treatment. The scale ranges from 0 (no pain) to 10(worse pain).&#xD;
A score of 0 will represent absence of pain and 10 will represent maximal pain.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Cutaneous Lupus</condition>
  <arm_group>
    <arm_group_label>532nm laser and topical corticosteroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1064nm laser and topical corticosteroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical corticosteroid alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical corticosteroid is applied to the patient's lesion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>532nm laser</intervention_name>
    <description>532nm laser will be used to treat the lesion in this study arm.</description>
    <arm_group_label>532nm laser and topical corticosteroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1064nm laser</intervention_name>
    <description>1064nm laser will be used to treat the lesion in this study arm.</description>
    <arm_group_label>1064nm laser and topical corticosteroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical corticosteroid</intervention_name>
    <description>The topical corticosteroid will be used to treat the lesion in this study arm.</description>
    <arm_group_label>1064nm laser and topical corticosteroid</arm_group_label>
    <arm_group_label>532nm laser and topical corticosteroid</arm_group_label>
    <arm_group_label>Topical corticosteroid alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adult 18 years of age or older&#xD;
&#xD;
          -  Ability to rate level of pain&#xD;
&#xD;
          -  Ability to rate visual satisfaction&#xD;
&#xD;
          -  At least 2 active lesions of CLE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  New or change in systemic medication for cutaneous lupus in past 6 months&#xD;
&#xD;
          -  Allergy to triamcinolone or betamethasone dipropionate cream&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Currently a prisoner&#xD;
&#xD;
          -  Unable to read and speak English since consent will only be available in English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCF Health Lake Nona Office</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <results_first_submitted>May 11, 2021</results_first_submitted>
  <results_first_submitted_qc>June 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 21, 2021</results_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Central Florida</investigator_affiliation>
    <investigator_full_name>David Weinstein</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology</investigator_title>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03639857/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03639857/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>We had planned to enroll 7 participants but due to lack of resources/support the study ended early with only 3 participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>532nm Laser and Topical Corticosteroid</title>
          <description>532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.&#xD;
532nm laser: 532nm laser will be used to treat the lesion in this study arm.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
        </group>
        <group group_id="P2">
          <title>1064nm Laser and Topical Corticosteroid</title>
          <description>1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.&#xD;
1064nm laser: 1064nm laser will be used to treat the lesion in this study arm.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
        </group>
        <group group_id="P3">
          <title>Topical Corticosteroid Alone</title>
          <description>Topical corticosteroid is applied to the patient's lesion.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All study participants received treatment of 2 or 3 lesions of cutaneous lupus depending upon their skin type.&#xD;
Participants with skin type 1, 2 or 3 received treatment of 3 lesions:&#xD;
One lesion treated with 532nm laser&#xD;
One lesion treated with the 1064nm laser&#xD;
One lesion treated with topical corticosteroid&#xD;
Participants with skin type 4, 5 or 6 received treatment of 2 lesions&#xD;
One lesion treated with the 1064nm laser&#xD;
One lesion treated with topical corticosteroid</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Lesions</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Limited CLASI</title>
        <description>The investigators are using a limited Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scoring system to classify specific lesions the investigators are measuring. The total limited CLASI reflects the sum of both active and damage CLASI, resulting in a score ranging from 0 to 8. A higher score indicates more severe disease. Score is assessed by the investigators.&#xD;
The limited active CLASI for a lesion will include the following:&#xD;
Erythema (ranging from 0 = absent to 3 = dark red/purple)&#xD;
Scale/Hypertrophy (ranging from 0 = absent to 2 = verrucous/ hypertrophic)&#xD;
The addition of these scores result in a total limited active CLASI score of the studied lesion, ranging from 0 to 5.&#xD;
The limited damage CLASI for a lesion will include the following:&#xD;
Dyspigmentation (0 = absent or 1 = present)&#xD;
Scarring/Atrophy/Panniculitis (ranging from 0 = absent to 2 = severely atrophic scarring or panniculitis).&#xD;
The addition of these scores result in a</description>
        <time_frame>2 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>532nm Laser and Topical Corticosteroid</title>
            <description>532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.&#xD;
532nm laser: 532nm laser will be used to treat the lesion in this study arm.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
          </group>
          <group group_id="O2">
            <title>1064nm Laser and Topical Corticosteroid</title>
            <description>1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.&#xD;
1064nm laser: 1064nm laser will be used to treat the lesion in this study arm.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
          </group>
          <group group_id="O3">
            <title>Topical Corticosteroid Alone</title>
            <description>Topical corticosteroid is applied to the patient's lesion.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Limited CLASI</title>
          <description>The investigators are using a limited Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scoring system to classify specific lesions the investigators are measuring. The total limited CLASI reflects the sum of both active and damage CLASI, resulting in a score ranging from 0 to 8. A higher score indicates more severe disease. Score is assessed by the investigators.&#xD;
The limited active CLASI for a lesion will include the following:&#xD;
Erythema (ranging from 0 = absent to 3 = dark red/purple)&#xD;
Scale/Hypertrophy (ranging from 0 = absent to 2 = verrucous/ hypertrophic)&#xD;
The addition of these scores result in a total limited active CLASI score of the studied lesion, ranging from 0 to 5.&#xD;
The limited damage CLASI for a lesion will include the following:&#xD;
Dyspigmentation (0 = absent or 1 = present)&#xD;
Scarring/Atrophy/Panniculitis (ranging from 0 = absent to 2 = severely atrophic scarring or panniculitis).&#xD;
The addition of these scores result in a</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O3" value="4.3" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O2" value="3.66" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O3" value="4" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O2" value="3.66" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O3" value="4.33" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>VAS for Appearance</title>
        <description>The investigators are using a VAS (visual analog scale) to measure patient assessment of the appearance of the lesion. The scale ranges from 0-10, with 10 being very satisfied and 0 being no satisfaction at all.&#xD;
A score of 0 will represent a cosmetically fully unsatisfactory result and 10 will represent cosmetically excellent result.</description>
        <time_frame>2 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>532nm Laser and Topical Corticosteroid</title>
            <description>532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.&#xD;
532nm laser: 532nm laser will be used to treat the lesion in this study arm.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
          </group>
          <group group_id="O2">
            <title>1064nm Laser and Topical Corticosteroid</title>
            <description>1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.&#xD;
1064nm laser: 1064nm laser will be used to treat the lesion in this study arm.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
          </group>
          <group group_id="O3">
            <title>Topical Corticosteroid Alone</title>
            <description>Topical corticosteroid is applied to the patient's lesion.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS for Appearance</title>
          <description>The investigators are using a VAS (visual analog scale) to measure patient assessment of the appearance of the lesion. The scale ranges from 0-10, with 10 being very satisfied and 0 being no satisfaction at all.&#xD;
A score of 0 will represent a cosmetically fully unsatisfactory result and 10 will represent cosmetically excellent result.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="7.5" upper_limit="7.5"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.4" upper_limit="6.3"/>
                    <measurement group_id="O3" value="4.2" lower_limit="1.8" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="10" upper_limit="10"/>
                    <measurement group_id="O2" value="7.5" lower_limit="6.4" upper_limit="9"/>
                    <measurement group_id="O3" value="5.5" lower_limit="3.5" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="9" upper_limit="9"/>
                    <measurement group_id="O2" value="6.5" lower_limit="4" upper_limit="7.8"/>
                    <measurement group_id="O3" value="3.6" lower_limit="2" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>VAS for Pain</title>
        <description>The investigators are using a VAS (visual analog scale) to assess pain of the laser treatment. The participant rates the pain of the laser treatment. The scale ranges from 0 (no pain) to 10(worse pain).&#xD;
A score of 0 will represent absence of pain and 10 will represent maximal pain.</description>
        <time_frame>1 Month</time_frame>
        <population>The control arm did not receive any laser intervention, just a topical medication therefore the pain scale was not used.</population>
        <group_list>
          <group group_id="O1">
            <title>532nm Laser and Topical Corticosteroid</title>
            <description>532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.&#xD;
532nm laser: 532nm laser will be used to treat the lesion in this study arm.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
          </group>
          <group group_id="O2">
            <title>1064nm Laser and Topical Corticosteroid</title>
            <description>1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.&#xD;
1064nm laser: 1064nm laser will be used to treat the lesion in this study arm.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
          </group>
          <group group_id="O3">
            <title>Topical Corticosteroid Alone</title>
            <description>Topical corticosteroid is applied to the patient's lesion.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS for Pain</title>
          <description>The investigators are using a VAS (visual analog scale) to assess pain of the laser treatment. The participant rates the pain of the laser treatment. The scale ranges from 0 (no pain) to 10(worse pain).&#xD;
A score of 0 will represent absence of pain and 10 will represent maximal pain.</description>
          <population>The control arm did not receive any laser intervention, just a topical medication therefore the pain scale was not used.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="6" upper_limit="6"/>
                    <measurement group_id="O2" value="2.13" lower_limit="1" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events and All-Cause Mortality were assessed for 8 weeks of treatment and 1 month after for follow-up.</time_frame>
      <desc>This was only a moderate risk study for the participants as only a lower energy laser was used on the skin.</desc>
      <group_list>
        <group group_id="E1">
          <title>532nm Laser and Topical Corticosteroid</title>
          <description>532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.&#xD;
532nm laser: 532nm laser will be used to treat the lesion in this study arm.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
        </group>
        <group group_id="E2">
          <title>1064nm Laser and Topical Corticosteroid</title>
          <description>1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.&#xD;
1064nm laser: 1064nm laser will be used to treat the lesion in this study arm.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
        </group>
        <group group_id="E3">
          <title>Topical Corticosteroid Alone</title>
          <description>Topical corticosteroid is applied to the patient's lesion.&#xD;
Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Weinstein</name_or_title>
      <organization>University of Central Florida College of Medicine</organization>
      <phone>407-266-4900</phone>
      <email>david.weinstein@ucf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

